- Home
- CLDI vs AKTX Comparison
CLDI vs AKTX Comparison
Compare CLDI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- AKTX
- Stock Information
- Founded
- CLDI 2014
- AKTX N/A
- Country
- CLDI United States
- AKTX United States
- Employees
- CLDI N/A
- AKTX N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- AKTX Health Care
- Exchange
- CLDI Nasdaq
- AKTX Nasdaq
- Market Cap
- CLDI 10.2M
- AKTX 41.8M
- IPO Year
- CLDI N/A
- AKTX N/A
- Fundamental
- Price
- CLDI $0.25
- AKTX $1.17
- Analyst Decision
- CLDI
- AKTX
- Analyst Count
- CLDI 0
- AKTX 0
- Target Price
- CLDI N/A
- AKTX N/A
- AVG Volume (30 Days)
- CLDI 1.6M
- AKTX 27.5K
- Earning Date
- CLDI 08-12-2025
- AKTX 08-18-2025
- Dividend Yield
- CLDI N/A
- AKTX N/A
- EPS Growth
- CLDI N/A
- AKTX N/A
- EPS
- CLDI N/A
- AKTX N/A
- Revenue
- CLDI N/A
- AKTX N/A
- Revenue This Year
- CLDI N/A
- AKTX N/A
- Revenue Next Year
- CLDI N/A
- AKTX N/A
- P/E Ratio
- CLDI N/A
- AKTX N/A
- Revenue Growth
- CLDI N/A
- AKTX N/A
- 52 Week Low
- CLDI $0.20
- AKTX $0.85
- 52 Week High
- CLDI $3.89
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- CLDI 30.55
- AKTX 45.49
- Support Level
- CLDI $0.20
- AKTX $1.10
- Resistance Level
- CLDI $0.25
- AKTX $1.18
- Average True Range (ATR)
- CLDI 0.03
- AKTX 0.07
- MACD
- CLDI -0.00
- AKTX 0.00
- Stochastic Oscillator
- CLDI 28.48
- AKTX 53.25
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.